Print this page
breast
-
Phase 2 Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) during First-Line Treatment of Advanced Biliary Tract Cancers.
Protocol: 072401Principal Investigator:
-
Howard Hochster
Applicable Disease Sites: Other Digestive Organ -
A Phase 1/Randomized Phase 2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma.
Protocol: 072403Principal Investigator:
-
Matthew Deek
Applicable Disease Sites: Pancreas -
A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer.
Protocol: 082203Principal Investigator:
-
Ryan Stephenson
Applicable Disease Sites: Kidney -
A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy.
Protocol: 082210Principal Investigator:
-
Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
A Randomized Phase III Trial oflntravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naive High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE).
Protocol: 082303Principal Investigator:
-
Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
A Phase I Study to Evaluate the Safety of Naltrexone and Propranolol in Combination with Standard of Care Ipilimumab and Nivolumab in Patients with Advanced Melanoma.
Protocol: 092302Principal Investigator:
-
Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO).
Protocol: 092305Principal Investigator:
-
Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2).
Protocol: 092401Principal Investigator:
-
Vadim Koshenkov
Applicable Disease Sites: Soft Tissue -
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-ZZFX (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma.
Protocol: 102301Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Other Female Genital -
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status.
Protocol: 102302Principal Investigator:
-
Aliza Leiser
Applicable Disease Sites: Other Female Genital -
A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial.
Protocol: 102403Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Any Site
Other Female Genital -
A Randomized, Open-Label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Participants with Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy.
Protocol: 102404Principal Investigator:
-
Aliza Leiser
Applicable Disease Sites: Other Female Genital -
A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers.
Protocol: 102405Principal Investigator:
-
Aliza Leiser
Applicable Disease Sites: Ovary -
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.
Protocol: 111702Principal Investigator:
-
Nehal Parikh
Applicable Disease Sites: Any Site
Ovary
Prostate -
A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL).
Protocol: 111707Principal Investigator:
-
Archana Sharma
Applicable Disease Sites: Lymphoid Leukemia -
Phase 1/2 Study to Evaluate Palbociclib (IBRANCE®) in Combination with Irinotecan and Temozolomide or in Combination with Topotecan and Cyclophosphamide in Pediatric Patients with Recurrent or Refractory Solid Tumors.
Protocol: 111901Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Any Site